Latest Merck Stories
BOSTON, April 17, 2014 /PRNewswire/ -- Columbia Laboratories, Inc.
Full-featured smartphone versions of popular app for doctors to include free access to The Merck Manual READING, Mass., April 16, 2014 /PRNewswire/ --
MONROVIA, Calif., April 10, 2014 /PRNewswire/ -- Xencor, Inc.
ROCKLAND, Massachusetts, April 7, 2014 /PRNewswire/ -- - First patient dosed in tecemotide Phase III trial; study recruiting
ROCKLAND, Mass., April 1, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the launch of the 10(th) edition of the EMD Serono Specialty
- Agreement aims to identify biomarkers relevant to future therapies in the area of Systemic Lupus Erythematosus and Lupus Nephritis ROCKLAND, Mass., April 1, 2014 /PRNewswire/
Data From Two Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented in Late-Breaking Clinical Trials Session at ACC.14 - Data Add to the Three Pivotal Studies Presented Yesterday THOUSAND
Pharmica Consulting, the industry leader in life science processes and technology, is pleased to announce that Arnaub Chatterjee of Merck will speak at Pharmica’s Pharma 3.0 – The Digital
LONDON, March 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
ANN ARBOR, Mich., March 26, 2014 /PRNewswire/ -- NanoBio Corporation today announced a licensing agreement with a subsidiary
- The act of sweetening by admixture of some saccharine substance.